Huihe Medical Launches Global Firsts: C-Wave® and Vispearl® Featured in Artery Network's New Product Showcase Episode 85

HuiHe Healthcare, with its strong independent research and development capabilities, has made significant achievements in the fields of structural heart disease, coronary vascular intervention, peripheral vascular intervention, oncological vascular intervention, and intelligent intervention.Products with global firsts in various fields have obtained certification and entered commercialization, filling multiple market gaps in China and even globally.

Among themK-clip is the world's first tricuspid annuloplasty repair system., the product has been clinically applied over 300 times in 9 countries and regions including China, the United States, Canada, France, and Germany;C-Wave^®The intravascular shockwave catheter is the only Chinese shockwave brand in China that has both coronary and peripheral indications.；Vispearl^®Embosphere is the world's first full-size visible drug-loaded embolic microsphere.In addition to this, there is alsoWorld's First Bipolar Adjustable SheathS-wan。

August 15th (Thursday) 19:30 VCBeat New Product Review Session 85, featuringFounder of HuiHe Healthcare/CEO Lin Lin, HuiHe Healthcare Co-Founder/COO Liang Tao, HuiHe Healthcare Market Manager Pan WanmaThree Guests Bring HuiHe HealthcareProduct Promotion of Two Commercialized Products: C-Wave and Vispearl

HuiHe Healthcare's Suzhou Zhonghui Medical, independently developed byC-Wave^®The Shockwave Catheter System is the first shockwave brand in China to simultaneously have indications for both coronary and peripheral use, suitable for moderate to severe vascular calcification lesions in coronary and peripheral vessels.

C-Wave^®Shockwave Catheter System, used for the treatment of vascular calcified lesions, can be used alone or in combination with stents and other products. It features "flexible when encountering soft tissue, rigid when encountering hard tissue," capable of effectively fracturing calcification both internally and externally without causing damage to soft tissues.

· World's first, S-shaped spiral electrode arrangement

· One-button four-wave, releasing up to 320 shock waves

· Optimize vascular wall compliance, preserve intima intact, and remodel media

· Low-pressure dilation, high-pressure calcium cracking, instantaneous shock wave pressure 50 ATM 

Vispearl^®The visible embolic microspheres, which have full independent intellectual property rights, canX-ray visible embolic microspheres capable of loading multiple anti-tumor drugs simultaneously, suitable for TACE procedures in liver cancer treatment. With a minimum particle size of 40μm, they provide more precise embolization effects and a more stable drug release profile. Their visibility allows for identification and traceability, facilitating combination with other liver cancer treatments to maximize patient benefits.

· Smaller Particle Size, Faster Drug Loading

· Visible and Safer

· HuiHe Healthcare: Drug Delivery, Superior Efficacy

Scan the QR code on the poster to add the assistant and schedule a live broadcast!

Lin Lin
Founder and CEO of HuiHe Healthcare

· Master's degree from Jiaotong University School of Medicine; EMBA from China Europe International Business School;
·(Former) Cardiologist at Ruijin Hospital, Shanghai Jiao Tong University;
· With 20 years of clinical and R&D experience, participated in hundreds of interventional cardiac valve surgeries;
· Founded HuiHe Healthcare in 2019, HuiHe Healthcare was rated as "Shanghai Unicorn Enterprises”；
· Authorized 29 Chinese invention patents, 2 U.S. invention patents, 1 Canadian patent, 1 European patent, and 4 PCT pathways.

Liang Tao

HuiHe Healthcare Co-Founder, COO

· Beijing University of Chinese Medicine Clinical Medicine;

· With over 20 years of experience in sales and commercial management, serving as the sales head in multiple foreign enterprises;

· Is one of the pioneers in China's interventional valve market, establishing the market promotion model, terminal pricing, and training standards for internal technical staff and medical personnel in China's interventional valve market.

Pan Wanma

HuiHe Healthcare Market Manager

· Fudan University, Major in Pharmacology;

· Experience of new product launches from multiple listed medical companies;

· Familiar with the market of vascular intervention and tumor products, and has rich practical experience in product launch promotion and product strategy.

Shanghai Huihe Healthcare Technology Co., Ltd. is a technology-driven, globally leading R&D and manufacturing enterprise in the field of泛血管 (pan-vascular) devices. Focused on promoting domestically innovated medical devices to the world, it collaborates with doctors to bring health and happiness to patients.

The company owns four leading platforms in the industry: delivery systems, clinical medical technology, precision manufacturing, and global marketing. It has independently developed world-leading products in the fields of heart valve intervention, vascular intervention, electrophysiological intervention, drug delivery intervention, and intelligent intervention.

"VCBeat New Product Review" is a live streaming column that supports the launch of innovative medical products from healthcare companies. The column’s mission is to assist in the release of every milestone for innovative medical products. If your company has plans to launch an innovative medical product or announce a major milestone and would like to participate in the VCBeat New Product Review, please contact the assistant for more information.

Scan the QR code below to contact the assistant for live broadcast reservation (if already added, please ask the assistant directly).

Scan the QR code below to download the VCBeat app and register to watch the live stream.

Contact the assistant to send a live broadcast screenshot, and participate in the lucky draw for a chance to win [15-day trial membership of VCBeat Industry Think Tank].